scispace - formally typeset
C

Christopher M. Counter

Researcher at Duke University

Publications -  128
Citations -  21997

Christopher M. Counter is an academic researcher from Duke University. The author has contributed to research in topics: Telomere & Telomerase reverse transcriptase. The author has an hindex of 53, co-authored 124 publications receiving 20736 citations. Previous affiliations of Christopher M. Counter include McMaster University & Geron Corporation.

Papers
More filters
Journal ArticleDOI

Creation of human tumour cells with defined genetic elements

TL;DR: It is shown that the ectopic expression of the telomerase catalytic subunit (hTERT) in combination with two oncogenes results in direct tumorigenic conversion of normal human epithelial and fibroblast cells.

Telomere shortening associated withchromosome instability isarrested inimmortal cells whichexpress telomerase activity

TL;DR: The results suggest that chromosomes with short (TTAGGG)n tracts are recombinogenic, critically shortened telomeres may be incompatible with cell proliferation and stabilization of telomere length by telomerase may be required for immortalization.
Journal ArticleDOI

Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity.

TL;DR: In this article, the authors measured telomere length, telomerase activity and chromosome rearrangements in human cells before and after transformation with SV40 or Ad5 and found that telomeres shortened by approximately 65 bp/generation during the lifespan of the cultures.
Journal ArticleDOI

hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization

TL;DR: The cloning of a human gene, hEST2, that shares significant sequence similarity with the telomerase catalytic subunit genes of lower eukaryotes is reported, suggesting that the induction of hEST 2 mRNA expression is required for the telomersase activation that occurs during cellular immortalization and tumor progression.